Pacira BioSciences, Inc.
PCRX
$23.40
-$1.69-6.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 168.92M | 187.25M | 168.57M | 178.02M | 167.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 168.92M | 187.25M | 168.57M | 178.02M | 167.12M |
| Cost of Revenue | 36.55M | 63.78M | 57.97M | 46.19M | 49.22M |
| Gross Profit | 132.38M | 123.47M | 110.61M | 131.84M | 117.90M |
| SG&A Expenses | 86.78M | 79.61M | 74.33M | 68.13M | 72.03M |
| Depreciation & Amortization | 14.32M | 14.32M | 14.32M | 14.32M | 14.32M |
| Other Operating Expenses | 351.00K | -- | -- | -- | -- |
| Total Operating Expenses | 161.10M | 157.72M | 146.62M | 147.05M | 152.00M |
| Operating Income | 7.83M | 29.53M | 21.95M | 30.98M | 15.12M |
| Income Before Tax | 8.71M | 25.53M | -138.86M | 36.58M | 13.64M |
| Income Tax Expenses | 3.89M | 9.49M | 4.61M | 17.70M | 4.66M |
| Earnings from Continuing Operations | 4.81M | 16.04M | -143.47M | 18.89M | 8.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.81M | 16.04M | -143.47M | 18.89M | 8.98M |
| EBIT | 7.83M | 29.53M | 21.95M | 30.98M | 15.12M |
| EBITDA | 28.99M | 50.78M | 42.20M | 49.84M | 33.54M |
| EPS Basic | 0.10 | 0.35 | -3.11 | 0.41 | 0.19 |
| Normalized Basic EPS | 0.14 | 0.41 | 0.31 | 0.43 | 0.21 |
| EPS Diluted | 0.10 | 0.33 | -3.11 | 0.39 | 0.19 |
| Normalized Diluted EPS | 0.14 | 0.39 | 0.31 | 0.39 | 0.19 |
| Average Basic Shares Outstanding | 46.28M | 46.17M | 46.13M | 46.17M | 46.50M |
| Average Diluted Shares Outstanding | 46.53M | 49.04M | 46.13M | 50.54M | 52.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |